# Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels

> **NCT03771040** · PHASE3 · COMPLETED · sponsor: **AB Science** · enrollment: 347 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Masitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03771040
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2020-09
- **Final completion:** 2020-09
- **Target enrollment:** 347 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03771040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03771040, "Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03771040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*